Market capitalization | €20.00k |
Enterprise Value | €-3.20m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.25 |
EV/Sales (TTM) EV/Sales | -7.11 |
P/S ratio (TTM) P/S ratio | 0.04 |
P/B ratio (TTM) P/B ratio | 0.31 |
Revenue growth (TTM) Revenue growth | -92.80% |
Revenue (TTM) Revenue | €450.00k |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
1 Analyst has issued a forecast Epigenomics:
1 Analyst has issued a forecast Epigenomics:
Dec '22 | |
Current assets | 11 11 |
Fixed assets | 5.04 5.04 |
Total Assets | 16 16 |
Dec '22 | |
Equity | 10 10 |
Debt capital | 5.68 5.68 |
Total Capital | 16 16 |
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. It offers Epi proColon, a blood-based test for the early detection of colorectal cancer; Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer, Epi BiSKit, a kit for the preparation of purified, bisulfite-converted DNA and, HCCBloodTest, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma. The comapny was founded by Oliver Schacht, Christian Piepenbrock, Kurt Berlin, Jörn Walter, and Ivo Gut on April 30, 1997 and is headquartered in Berlin, Germany.
Head office | Germany |
CEO | Gregory Hamilton |
Employees | 34 |
Founded | 1997 |
Website | www.epigenomics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.